European journal of clinical pharmacology · 2026
Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network Meta-analysis.
СтатьяNetwork Meta-AnalysisСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shakir Ishwa, Shahzad Faizan, Shabbir Ahsan, Shahabuddin Saba, Shabbir Haroon, Karamat Sobia, Hulou Saad, Khalid Abdul Rauf, Ahmed Syed Ijlal
Аннотация
BACKGROUND AND PURPOSE: Episodic migraine is a neurological disorder characterized by recurrent, unilateral headaches that significantly impair quality of life. CGRP monoclonal antibodies, targeting calcitonin gene-related peptide (CGRP), have shown efficacy in preventing and treating episodic migraine.
METHODS: A systematic search of PubMed, Cochrane, and Embase databases was conducted in September 2024 to identify randomized controlled trials (RCTs) on CGRP monoclonal antibodies for episodic migraine. A network meta-analysis was performed to assess efficacy (change in monthly migraine days) and safety (incidence of adverse events). Odds ratios (ORs) and surface under the cumulative ranking curve (SUCRA) were calculated.
RESULTS: 16 studies with 9,123 participants were included. galcanezumab (240 mg) showed the highest efficacy (SMD = 0.5012, p < 0.0001). fremanezumab (225 mg) had the highest odds of ≥ 50% reduction in migraine days (OR = 3.1684, p < 0.0001). erenumab (28 mg) showed the best safety profile (OR = 0.6815, p = 0.2220). fremanezumab ranked highest in both efficacy (SUCRA = 84.6%) and safety (SUCRA = 61.8%).
CONCLUSION: fremanezumab offers the best balance of efficacy and safety. Further long-term studies are needed.
METHODS: A systematic search of PubMed, Cochrane, and Embase databases was conducted in September 2024 to identify randomized controlled trials (RCTs) on CGRP monoclonal antibodies for episodic migraine. A network meta-analysis was performed to assess efficacy (change in monthly migraine days) and safety (incidence of adverse events). Odds ratios (ORs) and surface under the cumulative ranking curve (SUCRA) were calculated.
RESULTS: 16 studies with 9,123 participants were included. galcanezumab (240 mg) showed the highest efficacy (SMD = 0.5012, p < 0.0001). fremanezumab (225 mg) had the highest odds of ≥ 50% reduction in migraine days (OR = 3.1684, p < 0.0001). erenumab (28 mg) showed the best safety profile (OR = 0.6815, p = 0.2220). fremanezumab ranked highest in both efficacy (SUCRA = 84.6%) and safety (SUCRA = 61.8%).
CONCLUSION: fremanezumab offers the best balance of efficacy and safety. Further long-term studies are needed.